Naltrexone/Bupropion + Placebo
ApprovedRecruiting 0 watching 0 views this week๐ฅ Hot
80
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Obesity; Drug
Conditions
Obesity; Drug, Obesity, Morbid
Trial Timeline
Jun 4, 2025 โ Aug 1, 2028
NCT ID
NCT06620562About Naltrexone/Bupropion + Placebo
Naltrexone/Bupropion + Placebo is a approved stage product being developed by Bausch Health for Obesity; Drug. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06620562. Target conditions include Obesity; Drug, Obesity, Morbid.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06620562 | Approved | Recruiting |
Competing Products
20 competing products in Obesity; Drug
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 52 |
| MK0557 | Merck | Phase 3 | 77 |
| AMG 786 | Amgen | Phase 1 | 32 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| Tirzepatide | Eli Lilly | Phase 2 | 52 |
| exenatide + Placebo | Eli Lilly | Approved | 85 |
| Brenipatide | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 28 |
| PG-102 | Rani Therapeutics | Phase 1 | 25 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 33 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 33 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 44 |
| Tirzepatide | Eli Lilly | Approved | 85 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 23 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 85 |